FDA gives Epizyme a green light on trial recruitment, but tazemetostat isn’t completely out of the woods yet
Epizyme is reporting that the FDA has lifted the partial hold it imposed on their clinical trial work for the lead drug tazemetostat, but it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
